Thrombocytopenia Treatment Market
Market Insights on Thrombocytopenia Treatment covering sales outlook, demand forecast & up-to-date key trends
Thrombocytopenia Treatment Market by Drug Class, Distribution Channel & Region | Forecast 2023 to 2033
Thrombocytopenia Treatment Market Snapshot (2023 to 2033)
During the projected period from 2023 to 2033, the global market for thrombocytopenia treatment is conjectured to surge at a CAGR of 5.2%. In 2033, the industry is forecasted to reach a valuation of US$ 10 Billion from US$ 6 Billion in 2023. Increased thrombocytopenia morbidity and mortality rates, inexpensive thrombocytopenia therapy, and rising knowledge of thrombocytopenia and its treatment are among the reasons driving the worldwide thrombocytopenia treatment market.
Blood clots are due to platelets in the blood. Thrombocytopenia is defined as an abnormally low platelet count in the blood due to the presence of any illness or ailment. Individuals with thrombocytopenia have delayed or no blood clotting. Because of the high prevalence of thrombocytopenia and growing knowledge of treatment alternatives, the worldwide thrombocytopenia treatment market is likely to grow considerably in the near future.
Thrombocytopenia symptoms include nosebleeds, bruises, redness, and bleeding in the gums and mouth. Thrombocytopenia is discovered using tests such as a complete blood count (CBC) and a blood clotting study. Furthermore, biopsy and bone marrow aspiration are used to diagnose thrombocytopenia. According to a study published in Professional Med J in 2014 titled Incidence of Thrombocytopenia, the prevalence of thrombocytopenia is greater in persons aged 60 years and older who had non-cirrhotic liver disease. However, rapid discovery, along with the capacity to clone thrombopoietin, has resulted in novel therapeutic worldwide treatment options.
|
Data Points |
Key Statistics |
|
Expected Market Value (2023) |
US$ 6 Billion |
|
Anticipated Forecast Value (2033) |
US$ 10 Billion |
|
Projected Growth Rate (2023 to 2033) |
5.2% CAGR |
Let us know your requirement to get
100% FREE customization
Thrombocytopenia Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for thrombocytopenia treatment is projected to increase at a CAGR of 5.2% during the forecast period between 2023 and 2033, reaching a total of US$ 10 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 4%.
Due to the high prevalence of thrombocytopenia and increased knowledge about treatment alternatives, the worldwide thrombocytopenia treatment market is likely to grow considerably in the near future. Stringent regulatory clearances, on the other hand, and thrombocytopenia diagnostic delays are factors restricting the worldwide thrombocytopenia treatment market.
Which are Some Prominent Drivers of Thrombocytopenia Treatment Market?
The Approval of Efficient and Safe Medications for Thrombocytopenia Therapy will provide the Thrombocytopenia Treatment Industry with a Boost
Treatment approaches are generally tailored to the underlying cause of thrombocytopenia. The underlying reason for thrombocytopenia is not always understood, especially in situations of severe bleeding. Shionogi Inc.'s Lusutrombopag, an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist, was approved by Japan's Pharmaceuticals and Medical Devices Agency in September 2015.
Lusutrombopag improved chronic liver disease (CLD) linked with thrombocytopenia in individuals undergoing invasive operations. Lusustrombopag operates exclusively on human thrombopoietin (TPO) receptors, stimulating signaling pathways that cause bone marrow cells to proliferate and differentiate into megakaryocytes. As a result, the blood platelet count rises. Patients using Lusustrombopag, on the other hand, had greater blood leukocyte and erythrocyte counts.
Furthermore, Rigel Pharmaceuticals, Inc. submitted an application to the FDA in June 2017 for a new oral experimental medication, Tavalisse (fostamatinib disodium). This medication is intended to treat individuals with chronic or persistent immune thrombocytopenia by inhibiting the spleen tyrosine kinase.
Another Novartis medicine, Eltrombopag, an oral, non-peptide thrombopoietin receptor agonist, has proven effectiveness and safety in individuals with persistent immune thrombocytopenia (CIT). This medication is licensed in the United States and registered in Europe. Eltrombopag at low dosage is effective and safe for CIT prevention. Long-term use of thrombopoietin (TPO) receptor agonists is safe for patients with chronic lymphocytic leukemia accompanied by immune thrombocytopenia, according to Case Reports Hematology, because they are non-immunosuppressive medications.
Growing Prevalence of Thrombocytopenia to Accelerate Market Growth
The global incidence of thrombocytopenia is driving the thrombocytopenia therapy market. Chronic Hepatitis C patients are at a substantially increased risk of developing thrombocytopenia. According to the World Health Organization (WHO), the prevalence of Hepatitis C was lower in the Americas and Europe in 2014 compared to Africa and Pakistan, where the incidence of chronic liver disease was 4-6% higher. Liver disease has emerged as a socioeconomic and worldwide health issue, affecting 60-80% of the population.
Furthermore, rising government support for fast-track approval in order to discover newer treatments for this disorder, as well as capital investments in the creation of new drugs by biotechnology and pharmaceutical companies, are expected to drive growth in the thrombocytopenia treatment market over the coming years.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich are the Trough Areas faced by the Thrombocytopenia Treatment Market?
Patent Expiration is a Key Obstacle, Stifling the Market Growth
The thrombocytopenia treatment market is predicted to slow considerably in 2023 due to patent expiry and the rising availability of generic Promacta and MabThera.
Region-wise Insights
How will Thrombocytopenia Treatment Market Demand progress in the Asia Pacific?
Rapidly Increasing Medical Tourism Business in Asia Pacific Widening Profit Margins
The Asia Pacific region is a particularly appealing market for thrombocytopenia treatment. Factors such as the rapidly increasing medical tourism business in Asia Pacific, particularly in India and China, are likely to draw patients from all over the world for treatment. The presence of a large patient pool in the Asia Pacific is likely to raise the risk of morbidity associated with thrombocytopenia in the area.
Furthermore, initiatives taken by governments in Asia Pacific countries to promote the healthcare sector in these countries benefits from foreign currency differences, and the availability of skilled and qualified workforce are among the factors expected to attract global players to the Asia Pacific thrombocytopenia treatment market in the near future. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 4.9% in the assessment period 2023 to 2033.
How attractive are Growth Prospects for Thrombocytopenia Treatment in North America?
Strong Lab Infrastructure and Fast Expanding Research in Anticoagulant Medicines
North America has seen significant revenue opportunities as a result of strong lab infrastructure and fast-expanding research in anticoagulant medicines. Pathophysiology has also benefited the area's healthcare system.
Growing public knowledge of the morbidity and mortality associated with heparin treatment in patients, particularly in heart surgery operating rooms, has hampered research in nations such as the United States. North America is expected to grow at a CAGR of 5.1% in the assessment period 2023 to 2033.
What Factors favoring the Growth of Thrombocytopenia Treatment in Europe?
Favorable Reimbursement Policies fuelling sales of Thrombocytopenia Treatment
Europe is the second leading market in thrombocytopenia treatments. The morbidity rate caused by thrombocytopenia is high in affluent nations, whereas the fatality rate is high in poor countries.
Favorable reimbursement policies, high healthcare spending, a well-structured regulatory framework, a high rate of compliance with defined regulations, the availability of highly advanced healthcare facilities, and high awareness of thrombocytopenia and its treatment are some of the factors propelling the thrombocytopenia treatment market in Europe. Thus, owing to the aforementioned reasons, the region is expected to grow at a CAGR of 5% in the assessment period 2023 to 2033.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-wise Insights
Which is the Most Preferred Drug Class Segment?
The Glucocorticoids Segment to enhance Sales Prospects
On the basis of drug class, the thrombocytopenia treatment market is segmented into glucocorticoids, lysosomal enzymes, and platelet-stimulating agents. Glucocorticoids are expected to hold the largest share of the market.
Glucocorticoids are the usual first-line therapy for people with immune thrombocytopenic purpura (ITP) because of their efficacy in boosting platelet count, cheap cost, and ease of administration.
Which is the Most Popular Distribution Channel in the Thrombocytopenia Treatment Market?
The Hospital Pharmacies Segment to Drive the Market Growth
On the basis of distribution channels, the thrombocytopenia treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to hold the lion’s share in the market due to their low price and easy availability.
On the other hand, the online pharmacies segment is likely to gain momentum during the forecast period, due to hefty discounts amid the soaring e-commerce sector.
Start-ups offering Thrombocytopenia Treatment
Key start-up players in the thrombocytopenia treatment are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. One of the key thrombocytopenia treatment start-ups is as follows:
- Sexton Biotechnologies is a firm headquartered in the United States that creates human platelet lysate products. Pathogen-free human platelet lysates (GPL) are a medium that lowers risks and increases downstream performance when compared to alternatives. Signata, the startup's gene therapy platform, uses closed automation to limit contamination concerns, gather batch records, and regulate operations with a flexible system.
Market Competition
The thrombocytopenia treatment industry has experienced potential clinical breakthroughs as a result of ongoing guidelines changes. The 2018 American Society of Hematology (ASH) Guideline recommended a variety of alternative anticoagulant alternatives for doctors to consider.
Current practice recommendations in industrialized countries have prompted the development of novel thrombin inhibitors and immunoassays. This has increased therapy possibilities for acute thrombocytopenia treatment. Top players intend to introduce new anticoagulants to improve healthcare team outcomes. Manufacturers of assays and pharmaceuticals are focusing on lowering the probability of thromboembolic consequences.
Key players in the thrombocytopenia treatment market are 3SBio Inc., Amgen Inc., Takeda Pharmaceutical Company, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd. and Merck & Co., Inc.
Recent Developments:
- In December 2021, Horizon Therapeutics Plc's board of directors and Amgen Inc.'s board of directors announced that they have agreed on the terms of a cash offer for the Company by Pillartree Limited (Acquirer Sub), a newly formed private limited company wholly owned by Amgen, which is unanimously recommended by the Company Board and pursuant to which Acquirer Sub will acquire the entire issued and to be issued
- In December 2020, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., a subsidiary of 3SBio Inc., and Verseau Therapeutics, Inc. announced the selection of a monoclonal antibody targeting VSIG4 as a license program under their partnership arrangement aimed at the creation and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a variety of cancers.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 6 Billion |
|
Market Value in 2033 |
US$ 10 Billion |
|
Growth Rate |
CAGR of 5.2% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US Billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Thrombocytopenia Treatment Industry Survey
By Drug Class:
- Glucocorticoids
- Lysosomal Enzyme
- Platelet Stimulating Agent
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Frequently Asked Questions
FMI projects the global thrombocytopenia treatment market to expand at a 5.2% value CAGR by 2033
The global thrombocytopenia treatment market is estimated at a market value of US$ 6 Billion
The global thrombocytopenia treatment market is expected to garner a market value of US$ 10 Billion
Asia Pacific to be the most lucrative for thrombocytopenia treatment market growth.
3SBio Inc., Amgen Inc., Takeda Pharmaceutical Company, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd. and Merck & Co., Inc are some prominent thrombocytopenia treatment market players.
North America is expected to grow at a CAGR of 5.1% in the assessment period 2023 to 2033.
Europe is expected to grow at a CAGR of 5% in the assessment period 2023 to 2033.
The glucocorticoids segment is expected to hold the largest market share for thrombocytopenia treatment in the forecast period 2023 to 2033.
Table of Content
1. Executive Summary | Thrombocytopenia Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Glucocorticoids
5.3.2. Lysosomal Enzyme
5.3.3. Platelet Stimulating Agent
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The USA
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. The United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Drug Class
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. The USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Drug Class
13.1.2.2. By Distribution Channel
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Drug Class
13.2.2.2. By Distribution Channel
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Drug Class
13.3.2.2. By Distribution Channel
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Drug Class
13.4.2.2. By Distribution Channel
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Drug Class
13.5.2.2. By Distribution Channel
13.6. The United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Drug Class
13.6.2.2. By Distribution Channel
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Drug Class
13.7.2.2. By Distribution Channel
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Drug Class
13.8.2.2. By Distribution Channel
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Drug Class
13.9.2.2. By Distribution Channel
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Drug Class
13.10.2.2. By Distribution Channel
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Drug Class
13.11.2.2. By Distribution Channel
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Drug Class
13.12.2.2. By Distribution Channel
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Drug Class
13.13.2.2. By Distribution Channel
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Drug Class
13.14.2.2. By Distribution Channel
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Drug Class
13.15.2.2. By Distribution Channel
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Drug Class
13.16.2.2. By Distribution Channel
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Drug Class
13.17.2.2. By Distribution Channel
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Drug Class
13.18.2.2. By Distribution Channel
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Drug Class
13.19.2.2. By Distribution Channel
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Drug Class
13.20.2.2. By Distribution Channel
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Drug Class
14.3.3. By Distribution Channel
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. 3SBio Inc.
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Amgen Inc.
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Takeda Pharmaceutical Company
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Bayer AG
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Boehringer Ingelheim GmbH
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Bristol-Myers Squibb Company
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Eisai Co., Ltd.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Hansa Medical AB
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Intas Pharmaceuticals Ltd.
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Merck & Co. Inc.
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 4: North America Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ million) Forecast by Drug Class, 2018 to 2033
Table 6: North America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 7: Latin America Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ million) Forecast by Drug Class, 2018 to 2033
Table 9: Latin America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 10: Europe Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ million) Forecast by Drug Class, 2018 to 2033
Table 12: Europe Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 13: Asia Pacific Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Market Value (US$ million) Forecast by Drug Class, 2018 to 2033
Table 15: Asia Pacific Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 16: MEA Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 17: MEA Market Value (US$ million) Forecast by Drug Class, 2018 to 2033
Table 18: MEA Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 3: Global Market Value (US$ million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ million) Analysis by Drug Class, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 10: Global Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ million) by Drug Class, 2023 to 2033
Figure 17: North America Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 18: North America Market Value (US$ million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ million) Analysis by Drug Class, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 25: North America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ million) by Drug Class, 2023 to 2033
Figure 32: Latin America Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 33: Latin America Market Value (US$ million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ million) Analysis by Drug Class, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 40: Latin America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ million) by Drug Class, 2023 to 2033
Figure 47: Europe Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 48: Europe Market Value (US$ million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ million) Analysis by Drug Class, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 55: Europe Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 58: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ million) by Drug Class, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ million) by Country, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Market Value (US$ million) Analysis by Drug Class, 2018 to 2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 70: Asia Pacific Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 73: Asia Pacific Market Attractiveness by Drug Class, 2023 to 2033
Figure 74: Asia Pacific Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: MEA Market Value (US$ million) by Drug Class, 2023 to 2033
Figure 77: MEA Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 78: MEA Market Value (US$ million) by Country, 2023 to 2033
Figure 79: MEA Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Market Value (US$ million) Analysis by Drug Class, 2018 to 2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 85: MEA Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 88: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 89: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
